Article ; Online: Direct oral anticoagulants and their antagonists in perioperative practice.
Current opinion in anaesthesiology
2023 Volume 36, Issue 4, Page(s) 394–398
Abstract: Purpose of review: Review management strategies for patients receiving nonvitamin K direct-acting oral anticoagulants (DOACs).: Recent findings: Updated clinical trials and guidelines continue to further define optimal management for patients on ... ...
Abstract | Purpose of review: Review management strategies for patients receiving nonvitamin K direct-acting oral anticoagulants (DOACs). Recent findings: Updated clinical trials and guidelines continue to further define optimal management for patients on DOACs requiring emergency surgery or procedural interventions. In addition, specific bleeding management strategies that include either specific or nonspecific antagonists are becoming available. Summary: Most currently used DOACs are factor Xa inhibitors and should be stopped for 24-48 h for elective surgical procedures in patients at risk for bleeding and potentially longer for dabigatran, depending on renal function. Idarucizumab, a specific dabigatran reversal agent, has been studied in surgical patients and is currently approved for use. For Xa inhibitors apixaban and rivaroxaban, although andexanet alfa is approved for medical bleeds, it is not approved for surgical patients, has a short duration of effect, and costs $12 500 per gram. When managing DOAC-treated patients requiring emergency surgery, when stopping the DOAC and delaying surgery is not feasible, standard approaches should include hemostatic, hemodynamic, and transfusional support. Due to higher risk associated with therapeutic agents used to manage DOAC-related bleeding, increasing data supports the potential off-label use of prothrombin complex concentrate (PCC). |
---|---|
MeSH term(s) | Humans ; Dabigatran/adverse effects ; Anticoagulants/adverse effects ; Rivaroxaban/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Factor Xa Inhibitors/adverse effects ; Administration, Oral |
Chemical Substances | Dabigatran (I0VM4M70GC) ; Anticoagulants ; Rivaroxaban (9NDF7JZ4M3) ; Factor Xa Inhibitors |
Language | English |
Publishing date | 2023-06-06 |
Publishing country | United States |
Document type | Review ; Journal Article |
ZDB-ID | 645203-6 |
ISSN | 1473-6500 ; 0952-7907 |
ISSN (online) | 1473-6500 |
ISSN | 0952-7907 |
DOI | 10.1097/ACO.0000000000001275 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2564: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.